comparative cytotoxic evaluation of free and sodium alginate nanoparticle-encapsulated icd-85 on primary lamb kidney cells

background: current anti-cancer drug therapy results in systemic side effects due to non-specific uptake by normal healthy noncancerous tissues. to alleviate this difficulty, many attempts have been devoted to the development of new delivery systems such as polymeric nanoparticles (nps). in this study, we prepared icd-85 nps based on sodium alginate and analyzed the cytotoxic activity of icd-85 nps relative to free icd-85 on primary lamb kidney cells. methods: icd-85 loaded sodium alginate nanoparticles were prepared by ionic gelation method and were characterized by the particle size, size distribution and fourier transform infrared (ft-ir) spectroscopy. the in vitro cytotoxicity was evaluated by mtt assay and membrane integrity was evaluated by measuring lactate dehydrogenase (ldh) activity. the morphological alterations of untreated and treated cells were assessed by light inverted microscope. results: mtt assay showed that icd-85 nps could significantly decrease the in vitro cytotoxicity on primary lamb kidney cells compared to the free icd-85. the ic 10 value at 72 hours was increased from 9±2.7 μ g/ml for free icd-85 to 52±4.3 μ g/ml for icd-85 nps. ldh assay demonstrated that free icd-85 had dose-dependent cytotoxicity on primary lamb kidney cells while icd-85 nps exhibited significantly decreased cytotoxicity at equivalent concentrations . moreover, morphological analysis showed no significant difference between control and treated cells with icd-85 nps . conclusion: based on the results obtained in the present study it can be concluded that encapsulation of icd-85 with sodium alginate nanoparticles can reduce its necrotic effect on primary lamb kidney cells. please cite this article as: zare mirakabadi a, moradhaseli s. comparative cytotoxic evaluation of free and sodium alginate nanoparticle encapsulated icd-85 on primary lamb kidney cells. iran j cancer prev. 2013; 6(3):151-9. references 1. nie s, xingy, kim gj, simons jw. nanotechnology applications in cancer. annu rev biomed eng. 2007; 9: 257-88. 2. saez-fernandez e, ruiz ma, arias jl. drug delivery systems based on poly (ε-caprolactone) for cancer treatment. ars pharm.  2009; 50(2): 83-96. 3. van vlerken le, amiji mm. multi-functional polymeric nanoparticles for tumour-targeted drug delivery. expert opin drug deliv. 2006; 3(2): 205-16. 4. mcneil se. nanotechnology for the biologists. j leukocyte biol. 2005; 78: 585-94. 5. zhang l, gu fx, chan jm, wang az, langer rs, farokhzad oc. nanoparticles in medicine: therapeutic applications and developments. clin pharm ther. 2008; 83(5): 761-9. 6. sparreboom a, scripture cd, trieu v, williams pj, de t, yang a, et al. comparative, preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitacel (abi-007) and paclitaxel formulated in cremophor (taxol). clin cancer res. 2005; 11: 4136-43. 7. leonard m, boisseson mrd, hubert p, dalenccon f, dellacherie e. hydrophobically modified alginate hydrogels as protein carriers with specific controlled release properties. j control release. 2004; 98: 395-405. 8. park jh, kwona s, nam jo, park rw, chung h, seo sb, et al. self-assembled nanoparticles based on glycol chitosan bearing 5h-cholanic acid for rgd peptide delivery. j control release. 2004; 95: 579-88. 9. rajaonarivony m, vauthier c, couarraze g, puisieux f, couvreur p. development of a new drug carrier made from alginate. j pharm sci. 1993; 82(9): 912-7. 10. cafaggi s, russo e, stefani r, leardi r, caviglioli g, parodi b, et al. preparation and evaluation of nanoparticles made of chitosan or n-trimethyl chitosan and a cisplatin–alginate complex. j control release. 2007; 121: 110-23. 11. zare mirakabadi a, mahdavi s, koohi mk, taghavian m. cytotoxic effect of icd-85 (venom-derived peptides) on mda-mb-231 cell line. j venom anim toxins incl trop dis. 2008; 14(4): 619-27. 12. koohi mk, zare mirakabadi a, moharrami m, hablolvarid mh. anticancer effect of icd-85 (venom derived peptides) on mda-mb231 cell line (in vitro) and experimental mice with breast cancer (in vivo). int j vet res. 2009; 3(1): 49-54. 13. bradford m. a rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. anal biochem. 1976; 72(1-2): 248-54. 14. mohammadpour dounighi n, behfar a, ezabadi a, zolfagharian h, heydari m. preparation of chitosan nanoparticles containing naja-naja oxiana snake venom. nanomedicine: nbm. 2010; 6: 137-43. 15. freshney ri. culture of animal cells: a manual of basic technique. 5th ed. wiley-liss, new york; 2005; 389-91. 16. mosmann t. rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. j immunol method. 1983; 65: 55-63. 17. srivastava v, negi as, kumar jk, gupta mm, suman ps, khanuja sps. plant-based anticancer molecules: a chemical and biological profile of some important leads. bioorg med chem. 2005; 13: 5892-908. 18. pilatova m, varinska l, perjesi p, sarissky m, mirossay l, solar p, et al. in vitro antiproliferative and antiangiogenic effects of synthetic chalcone analogues. toxicology in vitro. 2010; 24: 1347-55. 19. wang wx, ji yh. scorpion venom induces glioma cell apoptosis in vitro and inhibits glioma tumor growth in vivo. j neurooncol. 2005; 73: 1-7. 20. moradhaseli s, zare mirakabadi a, sarzaeem a, kamalzadeh m, haji hosseini r. cytotoxicity of icd-85 nps on human cervical carcinoma hela cells through caspase-8 mediated pathway. iran j pharm res. 2013; 12(1): 155-63. 21. zurlo j, arterburn lm. characterization of a primary hepatocyte culture system for toxicological studies. in vitro cell dev biol. 1996; 32: 211-20. 22. gombotz wr, wee sf. protein release from alginate matrices. adv drug deliver rev. 1998; 31(3): 267-85. 23. fana l, jiang l, xu y, zhou y, shen y, xie w, et al. synthesis and anticoagulant activity of sodium alginate sulfates. carbohyd polym . 2011; 83: 1797-803. 24. tiyaboonchai w. chitosan nanoparticles: a promising system for drug delivery. naresuan university journal. 2003; 11(3): 51-66. 25. sahoo sk, prusty ak. two important biodegradable polymers and their role in nanoparticle preparation by complex coacervation method- a review. int j pharm appl sci. 2010; 1(2): 1-8. 26. de s, robinson d. polymer relationships during preparation of chitosan-alginate and poly-l-lysine-alginate nanospheres. j control release. 2003; 89(1): 101-12. 27. jahanshahi m, babaei z. protein nanoparticle: a unique system as drug delivery vehicles.  afr j biotechnol. 2008; 7(25): 4926-34. 28. lu yh, su my, huang hy, li l, yuan cg. protective effects of the citrus flavanones to pc12 cells against cytotoxicity induced by hydrogen peroxide. neuroscience letters. 2010; 484: 6-11. 29. kumari a, yadav sk, yadav sc. biodegradable polymeric nanoparticles based drug delivery systems. colloids surf b: biointerfaces. 2010; 75(1): 1-18. 30. zuco v, supino r, righetti sc, cleris l, marchesi e, passerine-gambacorti c, et al. selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. cancer letters 2002; 175: 17-25. 31. sporn mb, suh n. chemoprevention of cancer. carcinogenesis. 2000; 21: 525-30. 32. baker j, ajani j, scotte f, winther d, martin m, aapro ms, et al. docetaxel-related side effects and their management. eur j oncol nurs. 2008; 12: 253-68. 33. zheng d, li x, xu h, lu x, hu y, fan w. study on docetaxel-loaded nanoparticles with high antitumor efficacy against malignant melanoma. acta biochim biophys sin. 2009; 41(7): 578-87. 34. brigger i, dubernet c, couvreur p. nanoparticles in cancer therapy and diagnosis. adv drug deliv rev. 2002; 54: 631-51. 35. mattheolabakis g, taoufik e, haralambous s, roberts ml, avgoustakis k. in vivo investigation of tolerance and antitumor activity of cisplatin-loaded plga-mpeg nanoparticles. eur j pharm biopharm. 2009; 71: 190-5. 36. park j, fong pm, lu j, russell ks, booth cj, saltzman wm, et al. pegylated plga nanoparticles for the improved delivery of doxorubicin. nanomed: nanotechnol biol med. 2009; 5: 410-8. 37. zhang x, burt hm, hoff dv, dexter d, mangold g, degen d, et al. an investigation of the antitumour activity and biodistribution of polymeric micellar paclitaxel. cancer chemother pharmacol. 1997; 40: 81-6. 38. li c, price je, milas l, hunter nr, ke s, yu df, et al. antitumor activity of poly(l-glutamic acid)-paclitaxel on syngeneic and xenografted tumors. clin cancer res. 1999; 5: 891-7.